In the assessment of 12-month price targets, analysts unveil insights for X4 Pharmaceuticals, presenting an average target of ...

XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Full Enrollment of Phase 3 4WARD Trial Expected in 2H25 X4 ...

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...

Reports Q4 revenue $1.4M vs. $0 last year. “As expected, 2024 was a transformative year for the company and our momentum has continued into ...

Q4 2024 Management View CEO Paula Ragan highlighted 2024 as a transformative year for X4 Pharmaceuticals, with the U.S. approval and launch of XOLREMDI (mavorixafor) for WHIM syndrome, a rare ...

Greetings and welcome to the X4 Pharmaceuticals fourth quarter and full year 2024 financial and operating results conference call. (Operator Instructions) and it is now my pleasure to turn to your ...

GameSir X4 Aileron: one-minute review. T he GameSir X4 Aileron is a mobile controller purpose-built for cloud gaming on an ...

X4 Pharmaceuticals, Inc. (XFOR) on Tuesday reported a loss of $39.8 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of ...

If you buy something via one of our links, we may earn a commission. As a massive fan of the Insta360 X3, I was thrilled when a brand-new X4 arrived at my doorstep for testing earlier this season. The ...

Before thousands of people flock to downtown Salt Lake City to attend the Qualtrics X4 summit, the Provo-born company on ...

If you buy something via one of our links, we may earn a commission. As a massive fan of the Insta360 X3, I was thrilled when a brand-new X4 arrived at my doorstep for testing earlier this season. The ...